NEW YORK, Sept 20 (Reuters) - The maker of Skittles candies on Tuesday objected to a social media post by Donald Trump Jr. in which the Republican presidential hopeful's son compared admitting Syrian refugees to the United States to eating poisoned pieces of the brightly colored, fruit-flavored treats.

(Reuters) - U.S. retailers are taking a cautious view of the holiday selling season this year - if their temporary hiring plans are anything to go by.

DETROIT, Sept 20 (Reuters) - General Motors Co on Tuesday announced its Chevrolet Bolt electric vehicle will cost under $30,000 after tax breaks, a price that makes it significantly cheaper than the average new U.S. vehicle and sets up a test of whether the technology can go mainstream in the United States.

FRANKFURT, Sept 20 (Reuters) - German drugmaker Bayer said its two best-selling drugs had a higher annual peak sales potential than previously targeted, after the agreed $66 billion takeover of Monsanto stirred criticism it might neglect its pharmaceuticals business.

BRUSSELS (Reuters) - Alphabet's Google has been given an extra three weeks to respond to EU antitrust charges that it abused its dominant Android mobile operating system to squeeze out rivals, the European Commission said on Tuesday.

TORONTO, Sept 20 (Reuters) - Oil company Enbridge Inc's Northern Gateway pipeline project will not appeal a recent Canadian Federal Court of Appeal decision that reversed its approval pending consultations with aboriginal groups, it said on Tuesday.

WARSAW (Reuters) - Netflix Inc is expanding its Polish service to include more content subtitled or dubbed in Polish and plans to produce local shows before the end of the decade as the U.S. service seeks more subscribers away from its home market.

BERLIN (Reuters) - Volkswagen division MAN will next year start selling heavy-duty commercial vehicles with new digital services to make its trucks more efficient, as VW looks to challenge rivals Daimler and Volvo AB.

(Reuters) - Amgen Inc said on Tuesday its potent new cholesterol fighter, Repatha, met the primary and secondary goals of a study designed to show it can decrease plaque buildup in heart arteries of patients already taking widely used statin drugs, such as Lipitor.